Quantum-Si incorporated (QSI) 10-Year Financial Performance & Capital Metrics

QSI • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutQuantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.Show more

Revenue $3M +182.6%
EBITDA -$104M +2.8%
Net Income -$101M -5.3%
EPS (Diluted) -0.71 -4.4%
Gross Margin 52.32% +16.0%
EBITDA Margin -3400.13% +65.6%
Operating Margin -3550.56% +65.4%
Net Margin -3303.04% +62.8%
ROE -41.48% -36.2%
ROIC -49.03% -30.8%
Debt/Equity 0.06 +6.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 19 (bottom 19%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM40.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-29.93%

EPS CAGR

10Y-

5Y-

3Y-

TTM-5.4%

ROCE

10Y Avg-57.34%

5Y Avg-48.17%

3Y Avg-34.72%

Latest-42.06%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	1.08M	3.06M
Revenue Growth %	-	-	-	-	-	1.83%
Cost of Goods Sold+	0	0	0	0	594K	1.46M
COGS % of Revenue	-	-	-	-	0.55%	0.48%
Gross Profit+	0	0	0	0	488K	1.6M
Gross Margin %	-	-	-	-	0.45%	0.52%
Gross Profit Growth %	-	-	-	-	-	2.28%
Operating Expenses+	36.62M	36.69M	96.91M	123.84M	111.66M	110.18M
OpEx % of Revenue	-	-	-	-	103.2%	36.03%
Selling, General & Admin	8.52M	9.14M	50.33M	42.3M	44.63M	50.53M
SG&A % of Revenue	-	-	-	-	41.25%	16.53%
Research & Development	28.1M	27.55M	46.58M	72.06M	67.03M	59.64M
R&D % of Revenue	-	-	-	-	61.95%	19.5%
Other Operating Expenses	5K	-10K	0	9.48M	0	0
Operating Income+	-36.62M	-36.69M	-96.91M	-123.84M	-111.17M	-108.58M
Operating Margin %	-	-	-	-	-102.75%	-35.51%
Operating Income Growth %	-	-0%	-1.64%	-0.28%	0.1%	0.02%
EBITDA+	-35.84M	-35.8M	-95.87M	-121.26M	-107.02M	-103.98M
EBITDA Margin %	-	-	-	-	-98.9%	-34%
EBITDA Growth %	-	0%	-1.68%	-0.26%	0.12%	0.03%
D&A (Non-Cash Add-back)	780K	894K	1.04M	2.58M	4.16M	4.6M
EBIT	-36.62M	-36.69M	-94.98M	-114.36M	-95.96M	-108.58M
Net Interest Income+	0	79K	-5K	0	0	0
Interest Income	0	88K	0	0	0	0
Interest Expense	0	9K	5K	0	0	0
Other Income/Expense	828K	78K	1.92M	-8.6M	15.21M	7.63M
Pretax Income+	-35.79M	-36.61M	-94.99M	-132.44M	-95.96M	-100.95M
Pretax Margin %	-	-	-	-	-88.69%	-33.01%
Income Tax+	0	0	0	0	0	56K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-35.8M	-36.61M	-94.99M	-132.44M	-95.96M	-101.01M
Net Margin %	-	-	-	-	-88.69%	-33.03%
Net Income Growth %	-	-0.02%	-1.59%	-0.39%	0.28%	-0.05%
Net Income (Continuing)	-35.79M	-36.61M	-94.99M	-132.44M	-95.96M	-101.01M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.26	-6.81	-1.19	-0.95	-0.68	-0.71
EPS Growth %	-	-25.19%	0.83%	0.2%	0.28%	-0.04%
EPS (Basic)	-0.26	-6.81	-1.19	-0.95	-0.68	-0.71
Diluted Shares Outstanding	136.4M	5.38M	79.58M	139.26M	141.3M	143.2M
Basic Shares Outstanding	136.4M	5.38M	79.58M	139.26M	141.3M	143.2M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	33.87M	37.86M	477.17M	358.18M	266.31M	218.01M
Cash & Short-Term Investments	32.93M	36.91M	471.3M	351.31M	257.74M	209.6M
Cash Only	32.93M	36.91M	35.78M	84.32M	133.86M	49.24M
Short-Term Investments	0	0	435.52M	266.99M	123.88M	160.36M
Accounts Receivable	0	0	0	0	368K	1.33M
Days Sales Outstanding	-	-	-	-	124.14	159.11
Inventory	0	0	0	0	3.94M	4.07M
Days Inventory Outstanding	-	-	-	-	2.42K	1.02K
Other Current Assets	826K	0	0	6.87M	4.26M	3.01M
Total Non-Current Assets+	3.54M	2.73M	26.05M	33.3M	31.94M	29.86M
Property, Plant & Equipment	2.55M	2M	15.88M	32.61M	30.71M	29.05M
Fixed Asset Turnover	-	-	-	-	0.04x	0.11x
Goodwill	0	0	9.48M	0	0	0
Intangible Assets	0	0	0	0	532K	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	994K	738K	690K	697K	695K	808K
Total Assets+	37.41M	40.59M	503.23M	391.49M	298.25M	247.87M
Asset Turnover	-	-	-	-	0.00x	0.01x
Asset Growth %	-	0.09%	11.4%	-0.22%	-0.24%	-0.17%
Total Current Liabilities+	1.93M	2.75M	11.53M	15.71M	11.61M	18.19M
Accounts Payable	869K	1.33M	3.39M	3.9M	1.77M	1.93M
Days Payables Outstanding	-	-	-	-	1.09K	483.41
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	107K	579K	2.7M	88K	194K	514K
Current Ratio	17.57x	13.75x	41.39x	22.81x	22.94x	11.99x
Quick Ratio	17.57x	13.75x	41.39x	22.81x	22.60x	11.76x
Cash Conversion Cycle	-	-	-	-	1.46K	693.84
Total Non-Current Liabilities+	0	1.75M	14.66M	17.07M	15.02M	14.26M
Long-Term Debt	0	1.75M	0	0	0	0
Capital Lease Obligations	0	0	7.22M	16.08M	13.74M	9.25M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	7.45M	996K	1.28M	5.01M
Total Liabilities	1.93M	4.5M	26.19M	32.78M	26.63M	32.45M
Total Debt+	0	1.75M	8.08M	17.45M	15.3M	12.95M
Net Debt	-32.93M	-35.16M	-27.71M	-66.87M	-118.56M	-36.29M
Debt / Equity	-	0.05x	0.02x	0.05x	0.06x	0.06x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-4076.78x	-19381.60x	-	-	-
Total Equity+	35.46M	36.09M	477.03M	358.71M	271.62M	215.42M
Equity Growth %	-	0.02%	12.22%	-0.25%	-0.24%	-0.21%
Book Value per Share	0.26	6.71	5.99	2.58	1.92	1.50
Total Shareholders' Equity	35.46M	36.09M	477.03M	358.71M	271.62M	215.42M
Common Stock	1K	1K	14K	14K	14K	18K
Retained Earnings	-135.63M	-172.24M	-267.23M	-399.67M	-495.63M	-596.64M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	45K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-30.71M	-32.57M	-66.81M	-90.56M	-94.04M	-87.8M
Operating CF Margin %	-	-	-	-	-86.91%	-28.71%
Operating CF Growth %	-	-0.06%	-1.05%	-0.36%	-0.04%	0.07%
Net Income	-35.79M	-36.61M	-94.99M	-132.44M	-95.96M	-101.01M
Depreciation & Amortization	780K	894K	1.04M	2.58M	4.16M	4.6M
Stock-Based Compensation	2.71M	1.92M	24.92M	0	8.52M	8.89M
Deferred Taxes	0	0	714K	0	0	0
Other Non-Cash Items	501K	2K	36K	35M	-7.55M	-4.92M
Working Capital Changes	1.09M	1.22M	1.47M	4.3M	-3.19M	4.64M
Change in Receivables	0	0	0	0	-368K	-1.09M
Change in Inventory	0	0	0	0	286K	4.34M
Change in Payables	-270K	536K	709K	0	-1.22M	390K
Cash from Investing+	-1.24M	-461K	-450.94M	137.19M	143.43M	-32.67M
Capital Expenditures	-1.24M	-461K	-5.76M	-10.74M	-4.51M	-4.58M
CapEx % of Revenue	-	-	-	-	4.17%	1.5%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	-445.17M	0	-763K	-59K
Cash from Financing+	18.22M	37.01M	516.63M	1.91M	149K	35.88M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	65K	11K	5.61M	-848K	149K	1.09M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-31.95M	-33.03M	-72.58M	-101.3M	-99.31M	-92.38M
FCF Margin %	-	-	-	-	-91.78%	-30.21%
FCF Growth %	-	-0.03%	-1.2%	-0.4%	0.02%	0.07%
FCF per Share	-0.23	-6.14	-0.91	-0.73	-0.70	-0.65
FCF Conversion (FCF/Net Income)	0.86x	0.89x	0.70x	0.68x	0.98x	0.87x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-100.96%	-102.35%	-37.02%	-31.69%	-30.45%	-41.48%
Return on Invested Capital (ROIC)	-	-1593.41%	-32.28%	-25.06%	-37.48%	-49.03%
Gross Margin	-	-	-	-	45.1%	52.32%
Net Margin	-	-	-	-	-8868.76%	-3303.04%
Debt / Equity	-	0.05x	0.02x	0.05x	0.06x	0.06x
Interest Coverage	-	-4076.78x	-19381.60x	-	-	-
FCF Conversion	0.86x	0.89x	0.70x	0.68x	0.98x	0.87x
Revenue Growth	-	-	-	-	-	182.62%

Revenue by Segment

	2023	2024
Product	1.03M	2.92M
Product Growth	-	183.71%
Service	51K	133K
Service Growth	-	160.78%

Revenue by Geography

	2023	2024
Non-US	-	1.8M
Non-US Growth	-	-
UNITED STATES	-	1.2M
UNITED STATES Growth	-	-
Domestic	800K	-
Domestic Growth	-	-
International	300K	-
International Growth	-	-

Frequently Asked Questions

Growth & Financials

Quantum-Si incorporated (QSI) reported $3.2M in revenue for fiscal year 2024.

Quantum-Si incorporated (QSI) grew revenue by 182.6% over the past year. This is strong growth.

Quantum-Si incorporated (QSI) reported a net loss of $116.8M for fiscal year 2024.

Dividend & Returns

Quantum-Si incorporated (QSI) has a return on equity (ROE) of -41.5%. Negative ROE indicates the company is unprofitable.

Quantum-Si incorporated (QSI) had negative free cash flow of $105.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener